Clinical Trials Browser

Head and Neck Neoplasms × durvalumab × 30 days × Clear all

NCT03691714 2026-06-01

Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2 Completed

35 enrolled 13 charts

Head and Neck Neoplasms, Neoplasm Metastasis